Unfairness to Patients With Alzheimer Disease in Medicare's Coverage of Antiamyloid Immunotherapy

JAMA Neurol. 2022 Oct 1;79(10):962-963. doi: 10.1001/jamaneurol.2022.2131.

Authors

Andrew M Stern¹, Dennis J Selkoe¹

Affiliation

¹ Ann Romney Center for Neurologic Diseases, Division of Cognitive and Behavioral Neurology, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

PMID: 35913706
DOI: 10.1001/jamaneurol.2022.2131

No abstract available

Plain language summary

This Viewpoint discusses the US Center for Medicare and Medicaid Services’ decision on aducanumab, a drug that can treat Alzheimer disease.

MeSH terms

Aged
Alzheimer Disease* / therapy
Humans
Immunotherapy
Insurance Coverage
Medicare*
United States